Search
Ocadusertib
go.drugbank.com/drugs/DB21732InvestigationalOcadusertib has a monoisotopic molecular weight of 459.19 Da. … Ocadusertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Ocadusertib is a serine/threonine kinase inhibitor.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Clopenthixol
go.drugbank.com/drugs/DB13841InvestigationalClopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalOccurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
Vidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the … A nucleoside antibiotic isolated from Streptomyces antibioticus.
Synonyms: 9-β-D-arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-adenineInternational brands: Arasena-AAzatadine
go.drugbank.com/drugs/DB00719ApprovedWithdrawnAntihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- r...
Mixtures: X-TRI D, AFRINEX HADichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market
Synonyms: DCAEnasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalorally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexBisoprolol
go.drugbank.com/drugs/DB00612ApprovedInvestigational[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. … Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
Mixtures: CORBIS® D, BISOPROLOL PLUS 10/25 1AProducts: BISOPROLOL 5 1A PHARMA, BISOPROLOL 10 1A PHARMAOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationaltesting and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index